natgillin/translations-raw huggingface dataset:
Any capsules that have been frozen must be discarded. 
Kapsule, ki so bile zamrznjene, je treba zavreči.
Efficacy results are presented in Table 2 and Figures 1 and 2. 
Rezultati učinkovitosti so prikazani v preglednici 2 in na slikah 1 in 2.
• Take one dose (8 capsules) of Lynparza by mouth with water, once in the morning and once in the evening. 
• Zaužijte en odmerek (8 kapsul) zdravila Lynparza, z vodo, enkrat zjutraj in enkrat zvečer.
* Not controlled for multiplicity. 
* Ni kontrolirano za večkratne primerjave.
• if you have low blood cell counts on testing. 
• če imate na preiskavi majhno število krvnih celic.
Since it cannot be excluded that olaparib may reduce exposure to substrates of CYP2C9 through enzyme induction, the efficacy of some hormonal contraceptives may be reduced if co-administered with olaparib. 
Ker ni mogoče izključiti, da olaparib zaradi indukcije encimov zmanjša izpostavljenost substratom CYP2C9, je možno, da se učinkovitost nekaterih hormonskih kontraceptivov med sočasno uporabo z olaparibom zmanjša.
Your doctor will test your blood every month for the first year of treatment and at regular intervals after that. 
Zdravnik vam bo izvajal preiskave krvi vsak mesec prvo leto zdravljenja, pozneje pa v rednih presledkih.
• decrease in the number of platelets in blood (thrombocytopenia) - you may notice the following symptoms: 
• zmanjšanje števila trombocitov v krvi (trombocitopenija) - opazite lahko naslednje simptome:
Do not take Lynparza: 
Ne jemljite zdravila Lynparza:
• feeling short of breath, feeling very tired, pale skin or fast heart beat - these may be symptoms of a decrease in the number of red blood cells (anaemia). 
• kratka sapa, občutek hude utrujenosti, bledica kože ali hitro bitje srca - to so lahko simptomi zmanjšanja števila rdečih krvnih celic (anemije).
The gBRCAm status of patients enrolled via local testing was confirmed retrospectively by central testing. 
Status gBRCAm bolnic, vključenih z uporabo lokalnega testiranja, so retrospektivno potrdili s centralnim testiranjem.
• pain in the stomach area under the ribs (upper abdominal pain) 
• bolečine v predelu želodca pod rebri (v zgornjem delu trebuha)
• allergic reactions (e.g. hives, difficulty breathing or swallowing, dizziness which are signs and symptoms of hypersensitivity reactions). 
• alergijske reakcije (npr. koprivnica, težko dihanje ali požiranje, omotica, ki so znaki in simptomi preobčutljivostnih reakcij).
At the time of the PFS analysis, 1 patient had a confirmed partial response with a duration of response of 9.7 months in the olaparib arm. 
Ob času analize PFS je imel 1 bolnik potrjen delen odziv s trajanjem odziva 9,7 meseca v skupini z olaparibom.
• You should not take Lynparza if you are pregnant or might become pregnant. 
• Ne jemljite zdravila Lynparza, če ste noseči, ali če bi lahko zanosili.
Patients who had been treated with bevacizumab were excluded from the study, therefore there are no safety and efficacy data on olaparib patients who had previously received bevacizumab. 
Bolnice, zdravljene z bevacizumabom, so bile izključene iz študije, zato podatkov o varnosti in učinkovitosti olapariba pri bolnicah, ki so predhodno prejemale bevacizumab, ni.
Genetic testing should be conducted by an experienced laboratory using a validated test. 
Genetsko testiranje mora izvesti izkušen laboratorij z uporabo validiranega testa.
Lynparza should not be used during pregnancy. 
Zdravila Lynparza se ne sme uporabljati med nosečnostjo.
NR (24.1-NR) 
ND (24,1-ND)
This includes medicines obtained without a prescription and herbal medicines. 
To velja tudi za zdravila, ki ste jih dobili brez recepta, in za zdravila rastlinskega izvora.
Instead, alternative and error-prone pathways are activated, such as the non-homologous end joining (NHEJ) pathway, leading to increased genomic instability. 
Namesto tega se aktivirajo alternativne, napakam izpostavljene poti, npr. pot nehomolognega povezovanja koncev (NHEJ - non-homologous end joining), in to poveča genomsko nestabilnost.
The safety and efficacy of Lynparza in children and adolescents has not been established. 
Varnost in učinkovitost zdravila Lynparza pri otrocih in mladostnikih nista bili dokazani.
Treatment with Lynparza should be initiated and supervised by a physician experienced in the use of anticancer medicinal products. 
Zdravljenje z zdravilom Lynparza mora uvesti in nadzorovati zdravnik, ki ima izkušnje z uporabo zdravil proti raku.
• Take Lynparza once in the morning and once in the evening. 
• Zdravilo Lynparza vzemite enkrat zjutraj in enkrat zvečer.
Patients who experience these symptoms should observe caution when driving or using machines. 
Bolniki, ki imajo takšne simptome, morajo biti previdni glede vožnje in upravljanja strojev.
Patients in the olaparib group continued to receive treatment longer than those in the placebo group. 
Bolnice v skupini z olaparibom so nadaljevale zdravljenje dalj časa kot tiste v skupini s placebom.
The major primary target organ for toxicity in both species was the bone marrow, with associated changes in peripheral haematology parameters. 
Glavni ciljni organ toksičnosti je bil pri obeh živalskih vrstah kostni mozeg; to so spremljale spremembe perifernih hematoloških vrednosti.
Rarely, these may be a sign of more serious problems with the bone marrow such as ‘myelodysplastic syndrome' (MDS) or ‘acute myeloid leukaemia' (AML). 
Redko je to lahko znak resnejših težav s kostnim mozgom, na primer "mielodisplastičnega sindroma" (MDS) ali "akutne mieloične levkemije" (AML).
New metastatic breast cancer (%) Hormone receptor status (%) HR+ 
Lokalno napredovala Nov metastatski rak dojk (%) Stanje hormonskih receptorjev (%) HR+
If you notice any side effects not listed in this leaflet, please contact your doctor straight away. 
Če opazite kakšen neželen učinek, ki ni naveden v tem navodilu, se takoj posvetujte z zdravnikom.
Depending on the test used and the international classification consensus, the BRCA1/2 mutations have been classified as deleterious/suspected deleterious or pathogenic/likely pathogenic. 
Odvisno od uporabljenega testa in mednarodnega klasifikacijskega soglasja so bile mutacije genov BRCA1/2 opredeljene kot škodljive/domnevno škodljive ali patogene/verjetno patogene.
In the absence of BRCA1 or BRCA2 mutations, HRR pathway may be compromised by other mechanisms, although the causative aberrancy and penetrance are not fully elucidated. 
V odsotnosti mutacij gena BRCA1 ali BRCA2 lahko pot HRR okrnejo drugi mehanizmi, čeprav vzročna anomalija in penetrantnost nista povsem pojasnjeni.
Lynparza capsules can be stored for up to 3 months below 30°C. 
Kapsule zdravila Lynparza je mogoče do 3 mesece shranjevati pri temperaturi do 30 °C.
Lynparza tablets should be swallowed whole and not chewed, crushed, dissolved or divided. 
Tablete zdravila Lynparza je treba pogoltniti cele in se jih ne sme gristi, drobiti, raztapljati ali lomiti.
Previous anthracycline and taxane treatment 
Predhodno zdravljenje z antraciklinom in taksanom
This clastogenicity is consistent with the known pharmacology of olaparib and indicates potential for genotoxicity in man. 
Klastogenost se sklada z znano farmakologijo olapariba in kaže na potencialno genotoksičnost pri človeku.
In repeat-dose toxicity studies of up to 6 months duration in rats and dogs, daily oral doses of olaparib were well-tolerated. 
V študiji toksičnosti ponavljajočih se odmerkov v trajanju do 6 mesecev pri podganah in psih so živali dobro prenašale vsakodnevno peroralno uporabo olapariba.
Therefore, an additional non-hormonal contraceptive method should be considered during treatment (see section 4.5). 
Zato je treba razmisliti o dodatni nehormonski kontracepciji med zdravljenjem (glejte poglavje 4.5).
Ninety three percent (93%) of patients were randomised within 8 weeks of their last dose of platinum-based chemotherapy. 
Triindevetdeset odstotkov (93 %) bolnic je bilo randomiziranih v 8 tednih po njihovem zadnjem odmerku kemoterapije na osnovi platine.
PFS (DCO 30 June 
PFS (DCO 30. junij
Patients with evidence of disease at 2 years, who in the opinion of the treating physician can derive further benefit from continuous treatment, can be treated beyond 2 years. 
Bolnice, ki imajo po 2 letih znake bolezni in bi jim nadaljevanje zdravljenja po mnenju lečečega zdravnika dodatno koristilo, lahko zdravljenje prejemajo več kot 2 leti.
Consistent results were observed in the subgroups of patients by evidence of the disease at study entry. 
Pri podskupinah bolnic glede na dokaze bolezni ob vstopu v študijo so opažali dosledne rezultate.
The incidence of MDS/AML cases was similar among gBRCA1m and gBRCA2m patients (1.7% and 1.4%, respectively). 
Pojavnost primerov MDS/AML je bila pri bolnicah z gBRCA1m in gBRCA2m podobna (1,7 % pri prvih in 1,4 % pri drugih).
On multiple dosing there is no marked accumulation, with steady state exposures achieved within ~3 to 4 days. 
Po večkratnem odmerjanju ni izrazitega kopičenja in izpostavljenost v stanju dinamičnega ravnovesja je dosežena v ~3 do 4 dneh.
Clinical studies of olaparib in combination with other anticancer medicinal products, including DNA damaging agents, indicate a potentiation and prolongation of myelosuppressive toxicity. 
Klinične študije olapariba v kombinaciji z drugimi zdravili proti raku, vključno z zdravili, ki poškodujejo DNA, kažejo na okrepitev in podaljšanje mielosupresivne toksičnosti.
• looking for faulty DNA repair genes, such as BRCA (BReast CAncer) genes. 
• ugotavljanja okvarjenih genov za popravo DNA, na primer genov BRCA (BReast CAncer).
The potential for olaparib to induce CYP2C9, CYP2C19 and P-gp can also not be excluded. 
Prav tako ni mogoče izključiti možnosti, da olaparib inducira CYP2C9, CYP2C19 in P-gp.
PARP inhibitors can destroy cancer cells that are not good at repairing DNA damage. 
Zaviralci PARP lahko uničijo rakave celice, ki niso uspešne pri popravljanju okvare DNA.
• response to platinum chemotherapy, or 
• odziva na kemoterapijo s platino ali
BOTTLE/LABEL 
PLASTENKA/NALEPKA
The medicines listed here may not be the only ones that could affect Lynparza. 
Tukaj našteta zdravila niso edina, ki lahko vplivajo na delovanje zdravila Lynparza.
Effect of olaparib on other medicinal products 
Vpliv olapariba na druga zdravila
Therefore, olaparib upon co-administration may reduce the exposure to substrates of these metabolic enzymes and transport protein. 
Zato lahko olaparib po sočasni uporabi zmanjša izpostavljenost substratom teh presnovnih encimov in prenašalne beljakovine.
The incidence of anaemia adverse reactions was 22.8% (CTCAE grade ≥3 7.4%). 
Pojavnost neželenih učinkov z anemijo je bila 22,8 % (≥ 3. stopnje po CTCAE 7,4 %).
Treatment was continued until radiological progression of the underlying disease, unacceptable toxicity or for up to 2 years. 
Zdravljenje se je nadaljevalo do radiološkega napredovanja osnovne bolezni, nesprejemljive toksičnosti ali do največ 2 leti.
Proportion of patients event free 
Delež bolnic brez dogodka
• protease inhibitors boosted with ritonavir or cobicistat, boceprevir, telaprevir, nevirapine, 
• zaviralce proteaz okrepljene z ritonavirjem ali kobicistatom, boceprevir, telaprevir, nevirapin,
These may be low counts for red or white blood cells or low platelet counts. 
Lahko imate majhno število rdečih ali belih krvnih celic ali majhno število krvnih ploščic.
Chemotherapy (N = 97) Olaparib 300 mg twice daily (N = 205) 
Kemoterapija (N = 97) Olaparib 300 mg dvakrat na dan (N = 205)
Detection of BRCA mutation 
Ugotavljanje mutacije gena BRCA
Alu/Alu non-perforated blister containing 8 film-coated tablets. 
Alu/Alu neperforirani pretisni omot z 8 filmsko obloženimi tabletami.
Levels appeared to return to normal after treatment discontinuation and did not appear to have any clinical consequences. 
Vrednosti so se po prekinitvi zdravljenja normalizirale in po vsem sodeč ni bilo nobenih kliničnih posledic.
See section 4 for more information about these side effects, including the signs and symptoms you need to look out for (for example, fever or infection, bruising or bleeding). 
Za informacije o teh neželenih učinkih glejte poglavje 4, vključno z znaki in simptomi, na katere morate biti pozorni (npr. vročina ali okužba, podplutbe ali krvavitev).
BRCA mutation status should be determined by an experienced laboratory using a validated test method (see section 5.1). 
Mutacijsko stanje gena BRCA mora določiti izkušen laboratorij z validirano testno metodo (glejte poglavje 5.1).
• It is not known whether Lynparza passes into breast milk. 
• Ni znano, ali zdravilo Lynparza prehaja v materino mleko.
The analysis was performed using a Cox proportional hazards model with factors for treatment, ethnic descent, platinum sensitivity and response to final platinum therapy. 
Analiza je bila narejena s Coxovim modelom sorazmernih ogroženosti s faktorji za zdravljenje, etnično poreklo, občutljivost na platino in odziv na končno zdravljenje s platino.
On multiple dosing, an AUC accumulation ratio of 1.8 was observed and PK appeared to be time-dependent to a small extent. 
Med uporabo večkratnih odmerkov je bil opaženi akumulacijski delež AUC 1,8 in farmakokinetika je bila v majhni meri odvisna od časa.
The majority of the metabolism was attributable to oxidation reactions with a number of the components produced undergoing subsequent glucuronide or sulfate conjugation. 
Večina presnove poteka z oksidacijskimi reakcijami; pri tem nastanejo številne snovi, ki se nato konjugirajo z glukuronidom ali sulfatom.
Patients had tumour assessments at baseline and every 12 weeks for 3 years, and then every 24 weeks relative to date of randomisation, until objective radiological disease progression. 
Bolnicam so ocene tumorja opravili izhodiščno, 3 leta vsakih 12 tednov ter nato na 24 tednov glede na datum randomizacije, do objektivnega radiološkega napredovanja bolezni.
Missing Number of prior lines of chemotherapy for metastatic breast cancer (%) 
Število predhodnih kemoterapij za metastatskega raka dojk (%)
A pregnancy test should be performed on all women of childbearing potential prior to treatment and considered regularly throughout treatment. 
Pri vseh ženskah v rodni dobi je potrebno pred zdravljenjem opraviti test nosečnosti in ga redno izvajati med celotnim zdravljenjem.
efavirenz - used for viral infections, including HIV 
efavirenz - uporabljajo se za zdravljenje virusnih okužb, vključno s HIV,
Combination of olaparib with vaccines or immunosuppressant agents has not been studied. 
Sočasna uporaba olapariba s cepivi ali imunosupresivnimi zdravili ni raziskana.
No adjustment in starting dose is required for elderly patients. 
Starejšim bolnikom začetnega odmerka ni treba prilagoditi.
TNBC gBRCA mutation type (%) gBRCA1 gBRCA2 gBRCA1 and gBRCA2 ≥2 Metastatic sites (%) Location of the metastasis (%) Bone only 
Tip mutacije gBRCA (%) gBRCA1 gBRCA2 gBRCA1 in gBRCA2 ≥ 2 metastatski mesti (%) Mesto metastaz (%) Samo kosti
However, no dose adjustment is required on the basis of ethnicity (see section 5.2). 
Vendar odmerka ni treba prilagoditi glede na etnično poreklo (glejte poglavje 5.2).
Seven male patients were randomised (5 olaparib and 2 comparator). 
Randomiziranih je bilo 7 moških bolnikov (5 na olaparib in 2 na primerjalno zdravilo).
Median time to first onset of anaemia was approximately 4 weeks (approximately 7 weeks for CTCAE grade ≥3 events). 
Mediani čas do prvega pojava anemije je bil približno 4 tedne (približno 7 tednov za dogodke ≥ 3. stopnje po CTCAE).
For patients who remained in complete clinical response (i.e. no radiological evidence of disease), the maximum duration of treatment was 2 years; however, patients who had evidence of disease that remained stable (i.e. no evidence of disease progression) could continue to receive Lynparza beyond 2 years. 
Pri bolnicah, ki so ostale v popolnem kliničnem odzivu (tj. brez radioloških znakov bolezni), je bilo najdaljše trajanje zdravljenja 2 leti, bolnice z znaki bolezni, ki je ostala stabilna (tj. brez znakov napredovanja bolezni), pa so lahko zdravilo Lynparza prejemale več kot 2 leti.
The most common histological type was serous (> 90%), endometrioid histology was reported in 6% of the patients. 
Najpogostejša histološka vrsta je bila serozna (> 90 %), endometrioidna histologija pa je bila opisana pri 6 % bolnic.
The safety profile is based on pooled data from 1,826 patients with solid tumours treated with Lynparza monotherapy in clinical trials at the recommended dose. 
Varnostni profil temelji na kumulativnih podatkih 1826 bolnic s solidnimi tumorji, ki so bile v kliničnih preizkušanjih zdravljene z monoterapijo z zdravilom Lynparza v priporočenem odmerku.
A benefit was also observed in patients with BRCA1/2 wild-type/variants of uncertain significance (BRCA1/2 wt/VUS), although of a lesser magnitude. 
Korist so opažali tudi pri bolnicah z genom BRCA1/2 divjega tipa/variantami negotovega pomena (BRCA1/2 wt/VUS), čeprav manjše velikosti.
If you become pregnant during this time, you must talk to your doctor straight away. 
Če med tem časom zanosite, se morate nemudoma posvetovati z zdravnikom.
In animal studies, no effect on conception was observed but there are adverse effects on embryofoetal survival (see section 5.3). 
V študijah na živalih niso opažali vpliva na spočetje, ugotovljeni pa so neželeni učinki na embrio-fetalno preživetje (glejte poglavje 5.3).
Measurable disease (%) Progressive disease at time of randomization (%) Tumour grade at diagnosis Well differentiated (G1) Moderately differentiated (G2) Poorly differentiated (G3) Undifferentiated (G4) Unassessable (GX) 
Merljiva bolezen (%) Progresivna bolezen ob času randomizacije (%) Stopnja tumorja ob diagnozi Visoko diferenciran (G1) Zmerno diferenciran (G2) Slabo diferenciran (G3)
TSST- an approximation of PFS2 (DCO 09 May 
TSST - približek PFS2 (DCO 9. maj
No previous treatment with a PARP inhibitor, including olaparib, was permitted. 
Predhodno zdravljenje z zaviralci PARP, vključno z olaparibom, ni bilo dovoljeno.
If preferred, you can keep Lynparza capsules out of the refrigerator (below 30°C) for up to 3 months. 
Če vam bolj ustreza, lahko kapsule zdravila Lynparza največ 3 mesece shranjujete izven hladilnika (pri temperaturi do 30 °C).
• sore mouth (stomatitis). 
• vnetje v ustih (stomatitis)
• rifampicin, rifapentine, rifabutin - used for bacterial infections, including tuberculosis (TB) 
• rifampicin, rifapentin, rifabutin - uporabljajo se za zdravljenje bakterijskih okužb, vključno s tuberkulozo (TB),
The proportion of patients who progressed within 6 months of the last dose of platinum-based chemotherapy was 3.5% for olaparib and 8.4% for placebo. 
Delež bolnic, pri katerih je bolezen napredovala v 6 mesecih po zadnjem odmerku kemoterapije na osnovi platine, je bil za olaparib 3,5 % in za placebo 8,4 %.
Probability of progression free survival 
Verjetnost za preživetje brez napredovanja bolezni
Dose interruptions and reductions occurred most frequently in the first 3 months of treatment. 
Prekinitve uporabe in zmanjšanja odmerka so bili najpogostejši v prvih 3 mesecih zdravljenja.
Carcinogenicity Carcinogenicity studies have not been conducted with olaparib. 
Kancerogenost Študij kancerogenosti z olaparibom niso izvedli.
The study demonstrated a clinically relevant and statistically significant improvement in investigator assessed PFS for olaparib compared to placebo. 
Študija je pokazala klinično pomembno in statistično značilno izboljšanje PFS po oceni raziskovalca za olaparib v primerjavi s placebom.
If you forget to take Lynparza 
Če ste pozabili vzeti zdravilo Lynparza
Lynparza tablets may be taken without regard to meals. 
Tablete zdravila Lynparza je mogoče jemati ne glede na obroke.
Female partners of male patients must also use highly effective contraception if they are of childbearing potential (see section 4.4). 
Tudi partnerke moških bolnikov morajo uporabljati visoko učinkovito kontracepcijo, če so v rodni dobi (glejte poglavje 4.4).
If you are planning to breast-feed, tell your doctor. 
Če nameravate dojiti, morate to povedati zdravniku.
Combination with anastrozole, letrozole and tamoxifen A clinical study has been performed to assess the combination of olaparib with anastrozole, letrozole or tamoxifen. 
Kombinacija z anastrozolom, letrozolom in tamoksifenom Izvedli so klinično študijo za oceno kombinacije olapariba z anastrozolom, letrozolom in tamoksifenom.
In vitro, olaparib produced little/no inhibition of UGT1A4, UGT1A9, UGT2B7, or CYPs 1A2, 2A6, 2B6, 2C8, 2C9, 2C19, 2D6 or 2E1 and is not expected to be a clinically significant time dependent inhibitor of any of these CYP enzymes. 
In vitro je olaparib le malo ali sploh nič zavrl UGT1A4, UGT1A9, UGT2B7 ali CYP 1A2, 2A6, 2B6, 2C8, 2C9, 2C19, 2D6 ali 2E1 in ni pričakovati, da bi bil klinično pomemben časovno odvisen zaviralec katerega od encimov CYP.
• any other anticancer medicines 
• katero koli drugo zdravilo proti raku,
Also, some other medicines can affect the way Lynparza works. 
Tudi nekatera druga zdravila lahko vplivajo na delovanje zdravila Lynparza.
The secondary endpoints TFST and PFS2 demonstrated a persistent and statistically significant improvement for olaparib compared with placebo (Table 4). 
Sekundarna cilja študije TFST in PFS2 sta pokazala stalno in statistično značilno izboljšanje z olaparibom v primerjavi s placebom (preglednica 4).
Tests and checks Your doctor will check your blood before and during treatment with Lynparza. 
Preiskave in kontrole Zdravnik vam bo pred zdravljenjem in med zdravljenjem z zdravilom Lynparza kontroliral kri.
Interval debulking surgery was performed in 35% of the patients and of these 82% had no macroscopic residual disease reported. 
Intervalno je bila operacija za zmanjšanje tumorja opravljena pri 35 % teh bolnic in od teh jih 82 % ni imelo makroskopsko vidnih ostankov bolezni.
Paediatric population No studies have been conducted in paediatric patients. 
Pediatrična populacija Študij pri pediatričnih bolnikih niso izvedli.
It is not known whether Lynparza may affect the effectiveness of some hormonal contraceptives. 
Ni znano, ali zdravilo Lynparza poslabša učinkovitost nekaterih hormonskih kontraceptivov.
In cancers that lack functional components of HRR such as BRCA1 or 2, DNA DSBs cannot be repaired accurately or effectively. 
Pri raku, ki nima funkcionalnih elementov HRR, kot sta BRCA1 ali 2, točno in učinkovito popravilo DSB DNA ni mogoče.
Male patients: 
Moški bolniki:
It is recommended that treatment be continued until progression of the underlying disease or unacceptable toxicity. 
Zdravljenje je priporočljivo nadaljevati do napredovanja osnovne bolezni ali nesprejemljive toksičnosti.
What Lynparza is and how it works 
Kaj je zdravilo Lynparza in kako deluje
• Take Lynparza at least one hour after eating food. 
• Zdravilo Lynparza vzemite vsaj eno uro po jedi.
Lynparza with drink 
Zdravilo Lynparza skupaj s pijačo
(E172), iron oxide black (E172) (150 mg tablets only). 
(E172), črni železov oksid (E172) (samo 150 mg tablete).
Table 7 Patient demographic and baseline characteristics in OlympiAD 
Demografske in izhodiščne značilnosti bolnikov v študiji OlympiAD
Patients could have received prior bevacizumab, except in the regimen immediately prior to randomisation. 
Bolnice so predhodno lahko prejemale bevacizumab, razen v shemi tik pred randomizacijo.
Within each SOC, preferred terms are arranged by decreasing frequency and then by decreasing seriousness. 
Pri vsakem organskem sistemu so prednostni izrazi razvrščeni po padajoči pogostnosti in nato po padajoči resnosti.
Myelodysplastic syndrome/Acute myeloid leukaemia The overall incidence of myelodysplastic syndrome/acute myeloid leukaemia (MDS/AML) in patients treated in clinical trials with Lynparza monotherapy, including long-term survival follow-up, was <1.5% and the majority of events had a fatal outcome. 
Mielodisplastični sindrom/akutna mieloična levkemija Celokupna pojavnost mielodisplastičnega sindroma/akutne mieloične levkemije (MDS/AML - myelodysplastic syndrome/acute myeloid leukaemia) je bila pri bolnicah, ki so v kliničnih preizkušanjih prejemale monoterapijo z zdravilom Lynparza, vključno v obdobju dolgoročnega spremljanja preživetja, < 1,5 % in večina teh primerov je bila s smrtnim izidom.